A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol
Patients with symptomatic advanced chronic obstructive pulmonary disease (COPD) who experience recurrent exacerbations are particularly at risk of poor outcomes and present a significant burden on healthcare systems. The relative merits of treating with different inhaled combination therapies e.g. i...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
European Respiratory Society
2016
|
| _version_ | 1797086131415678976 |
|---|---|
| author | Pascoe, S Lipson, D Locantore, N Barnacle, H Brealey, N Mohindra, R Dransfield, M Pavord, I Barnes, N |
| author_facet | Pascoe, S Lipson, D Locantore, N Barnacle, H Brealey, N Mohindra, R Dransfield, M Pavord, I Barnes, N |
| author_sort | Pascoe, S |
| collection | OXFORD |
| description | Patients with symptomatic advanced chronic obstructive pulmonary disease (COPD) who experience recurrent exacerbations are particularly at risk of poor outcomes and present a significant burden on healthcare systems. The relative merits of treating with different inhaled combination therapies e.g. inhaled corticosteroids (ICS)/long-acting β2-agonist (LABA), LABA/long-acting muscarinic antagonists (LAMA), ICS/LABA/LAMA, in this patient group are poorly understood, as is reflected in current guidelines. The InforMing the PAthway of COPD Treatment (IMPACT) study will evaluate the efficacy and safety of fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) versus FF/VI or UMEC/VI over a 52-week treatment period. The study has been designed with a focus on understanding the comparative merits of each treatment modality in different phenotypes/endotypes.This is a phase III, randomised, double-blind, three-arm, parallel-group, global multicentre study comparing the rate of moderate and severe exacerbations between FF/UMEC/VI and FF/VI or UMEC/VI over a 52-week treatment period. The study aims to recruit 10 000 patients from approximately 1070 centres. Eligible patients are aged ≥40 years, with symptomatic advanced COPD (Global initiative for chronic Obstructive Lung Disease (GOLD) group D) and an exacerbation in the previous 12 months.The first patients were recruited to the IMPACT study (ClinicalTrials.gov: NCT02164513) in June 2014 and the anticipated completion date is July 2017. |
| first_indexed | 2024-03-07T02:17:41Z |
| format | Journal article |
| id | oxford-uuid:a2d48ccc-df98-4048-ba32-ea3933c7f3eb |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T02:17:41Z |
| publishDate | 2016 |
| publisher | European Respiratory Society |
| record_format | dspace |
| spelling | oxford-uuid:a2d48ccc-df98-4048-ba32-ea3933c7f3eb2022-03-27T02:22:38ZA phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocolJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:a2d48ccc-df98-4048-ba32-ea3933c7f3ebEnglishSymplectic Elements at OxfordEuropean Respiratory Society2016Pascoe, SLipson, DLocantore, NBarnacle, HBrealey, NMohindra, RDransfield, MPavord, IBarnes, NPatients with symptomatic advanced chronic obstructive pulmonary disease (COPD) who experience recurrent exacerbations are particularly at risk of poor outcomes and present a significant burden on healthcare systems. The relative merits of treating with different inhaled combination therapies e.g. inhaled corticosteroids (ICS)/long-acting β2-agonist (LABA), LABA/long-acting muscarinic antagonists (LAMA), ICS/LABA/LAMA, in this patient group are poorly understood, as is reflected in current guidelines. The InforMing the PAthway of COPD Treatment (IMPACT) study will evaluate the efficacy and safety of fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) versus FF/VI or UMEC/VI over a 52-week treatment period. The study has been designed with a focus on understanding the comparative merits of each treatment modality in different phenotypes/endotypes.This is a phase III, randomised, double-blind, three-arm, parallel-group, global multicentre study comparing the rate of moderate and severe exacerbations between FF/UMEC/VI and FF/VI or UMEC/VI over a 52-week treatment period. The study aims to recruit 10 000 patients from approximately 1070 centres. Eligible patients are aged ≥40 years, with symptomatic advanced COPD (Global initiative for chronic Obstructive Lung Disease (GOLD) group D) and an exacerbation in the previous 12 months.The first patients were recruited to the IMPACT study (ClinicalTrials.gov: NCT02164513) in June 2014 and the anticipated completion date is July 2017. |
| spellingShingle | Pascoe, S Lipson, D Locantore, N Barnacle, H Brealey, N Mohindra, R Dransfield, M Pavord, I Barnes, N A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol |
| title | A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol |
| title_full | A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol |
| title_fullStr | A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol |
| title_full_unstemmed | A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol |
| title_short | A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol |
| title_sort | phase iii randomised controlled trial of single dose triple therapy in copd the impact protocol |
| work_keys_str_mv | AT pascoes aphaseiiirandomisedcontrolledtrialofsingledosetripletherapyincopdtheimpactprotocol AT lipsond aphaseiiirandomisedcontrolledtrialofsingledosetripletherapyincopdtheimpactprotocol AT locantoren aphaseiiirandomisedcontrolledtrialofsingledosetripletherapyincopdtheimpactprotocol AT barnacleh aphaseiiirandomisedcontrolledtrialofsingledosetripletherapyincopdtheimpactprotocol AT brealeyn aphaseiiirandomisedcontrolledtrialofsingledosetripletherapyincopdtheimpactprotocol AT mohindrar aphaseiiirandomisedcontrolledtrialofsingledosetripletherapyincopdtheimpactprotocol AT dransfieldm aphaseiiirandomisedcontrolledtrialofsingledosetripletherapyincopdtheimpactprotocol AT pavordi aphaseiiirandomisedcontrolledtrialofsingledosetripletherapyincopdtheimpactprotocol AT barnesn aphaseiiirandomisedcontrolledtrialofsingledosetripletherapyincopdtheimpactprotocol AT pascoes phaseiiirandomisedcontrolledtrialofsingledosetripletherapyincopdtheimpactprotocol AT lipsond phaseiiirandomisedcontrolledtrialofsingledosetripletherapyincopdtheimpactprotocol AT locantoren phaseiiirandomisedcontrolledtrialofsingledosetripletherapyincopdtheimpactprotocol AT barnacleh phaseiiirandomisedcontrolledtrialofsingledosetripletherapyincopdtheimpactprotocol AT brealeyn phaseiiirandomisedcontrolledtrialofsingledosetripletherapyincopdtheimpactprotocol AT mohindrar phaseiiirandomisedcontrolledtrialofsingledosetripletherapyincopdtheimpactprotocol AT dransfieldm phaseiiirandomisedcontrolledtrialofsingledosetripletherapyincopdtheimpactprotocol AT pavordi phaseiiirandomisedcontrolledtrialofsingledosetripletherapyincopdtheimpactprotocol AT barnesn phaseiiirandomisedcontrolledtrialofsingledosetripletherapyincopdtheimpactprotocol |